WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1997039120) ANTISENSE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEFG/VPF) EXPRESSION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1997/039120    International Application No.:    PCT/US1997/006412
Publication Date: 23.10.1997 International Filing Date: 17.04.1997
Chapter 2 Demand Filed:    17.11.1997    
IPC:
A61K 38/00 (2006.01), A61K 48/00 (2006.01), C12N 15/11 (2006.01)
Applicants: ARONEX PHARMACEUTICALS, INC. [US/US]; 3400 Research Forest Drive, The Woodlands, TX 77381-4223 (US) (For All Designated States Except US).
HOECHST MARION ROUSSEL DEUTSCHLAND GMBH [DE/DE]; Brüningstrasse 50, D-65929Frankfurt am Main (DE) (For All Designated States Except US).
CHAUDHARY, Nilabh [US/US]; (US) (For US Only).
RAO, T., Sudhakar [US/US]; (US) (For US Only).
REVANKAR, Ganapathi, R. [US/US]; (US) (For US Only).
COSSUM, Paul, A. [AU/US]; (US) (For US Only).
RANDO, Robert, F. [US/US]; (US) (For US Only).
PEYMAN, Anusch [DE/DE]; (DE) (For US Only).
UHLMANN, Eugen [DE/DE]; (DE) (For US Only)
Inventors: CHAUDHARY, Nilabh; (US).
RAO, T., Sudhakar; (US).
REVANKAR, Ganapathi, R.; (US).
COSSUM, Paul, A.; (US).
RANDO, Robert, F.; (US).
PEYMAN, Anusch; (DE).
UHLMANN, Eugen; (DE)
Agent: SCHWAN, Gerhard; Elfenstrasse 32, D-81739 München (DE)
Priority Data:
60/015,752 17.04.1996 US
Title (EN) ANTISENSE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEFG/VPF) EXPRESSION
(FR) INHIBITEURS ANTISENS DE L'EXPRESSION DU FACTEUR DE CROISSANCE ENDOTHELIALE VASCULAIRE (VEGF-VPF)
Abstract: front page image
(EN)The present invention relates to the inhibition of vascular endothelial growth factor expression with oligonucleotides. The oligonucleotides of the present invention are thought to bind to target nRNA in a sequence specific manner and prevent expression of the encoded gene. Chemical modifications of the oligonucleotides for increasing their stability and binding efficiency are disclosed. These modifications increase the stability and the efficiency of the oligonucleotides contemplated in this invention. Oligonucleotides compositions can be used in $i(ex vivo) therapies for the treatment of macrophages or $i(in vivo) therapies by injection, inhalation, topical treatment or other routes of administration.
(FR)L'invention concerne l'inhibition de l'expression du facteur de croissance endothéliale vasculaire au moyen d'oligonucléotides. On pense que ces oligonucléotides se fixent à l'ARNm cible selon une séquence spécifique et empêchent l'expression du gène codé. L'invention concerne les modifications chimiques des oligonucléotides afin d'augmenter leur stabilité et leur efficacité de fixation. Ces modifications augmentent la stabilité et l'efficacité de ces oligonucléotides. On peut utiliser des compositions à base d'oligonucléotides dans des thérapies $i(ex vivo) pour le traitement de macrophages ou dans des thérapies $i(in vivo) par injection, inhalation, traitement localisé ou autres voies d'administration.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)